• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Arixtra

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Arixtra

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Arixtra, an injectable solution for subcutaneous use, has been approved as a preventative treatment for deep vein thrombosis (DVT) in adults undergoing hip fracture, hip replacement, or knee replacement surgery. It is adminstered through a single dose, prefilled syringe, affixed with an automatic needle protection system. Arixtra is the only antithrombotic agent approved in the United States for hip fracture surgery.

    DVT is caused by a blood clot forming in a deep vein in the leg. It may cause pain and swelling, and enlargement and discoloration of the veins. The clot can grow in size and block other veins. Most seriously, portions of the clot may break away and travel through the veins to the lungs, leading to a life threatening pulmonary embolism.

    Clinical Results

    International randomized, double-blind phase III trials evaluated the use of Arixtra in more than 7,000 subjects undergoing hip fracture, hip replacement or knee replacement surgeries. Results demonstrated Arixtra to provide a superior benefit in comparison to the reference treatment.

    Side Effects

    Adverse events associated with the use of Arixtra may include (but are not limited to) the following:


    • Bleeding complications
    • Mild irritation at injection site
    • Anemia
    • Fever
    • Nausea
    • Edema
    • Constipation

    Mechanism of Action

    Arixtra (fondaparinux sodium) exhibits antithrombotic activity, which is the result of antithrombin III (ATIII)-mediated selective inhibition of Factor Xa. By selectively binding to ATIII, fondaparinux sodium activates the innate neutralization of Factor Xa by ATIII. This neutralization interupts the blood coagulation cascade and thus inhibits thrombin formation and thrombus development.

    Additional Information

    For additional information on Arixtra, please visit Sanofi-Synthelabo.

    Approval Date: 2001-12-01
    Company Name: Organon, Sanofi-Synthelabo
    Back to Listings

    Upcoming Events

    • 26Jan

      Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

    • 27Jan

      Medical Device Clinical Trials in China: Latest Regulatory Developments

    • 11Feb

      Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • Virtual Doctoer

      Simple Changes Can Make Trials More Patient Friendly

    • Drug approval

      Two-Thirds of Trial Subjects for Drug Approvals Are Outside the U.S.

    • VaccinewithNeedle-360x240.png

      Rules of Vaccine Approval May Be Changing, But Statistical Analysis Tools Remain Constant

    • AskTheExperts-360x240.png

      Ask the Experts: Trial Operations Adjustments in a Remote World

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing